Fundraising Fox

Claris Biotherapeutics

Jersey City, US · Founded 2018 · Delaware corporation · 4 known investors

Biotech

Founders & leadership

HR
Henry RathExecutive
SO
Susan OrrExecutive
CA
Clarke AtwellNamed on SEC filing
SB
Stephen BradyNamed on SEC filing
MD
Michael DybbsNamed on SEC filing
MH
Matt HobsonNamed on SEC filing
MR
Maha RadhakrishnanNamed on SEC filing
BB
Brian BaumNamed on SEC filing

Board

KH
Kenneth HarrisonBoard director
MF
Meredith FisherBoard director
MD
Marc de GaridelBoard director
RD
Reza DanaBoard director

Investors · 4

Catalio Capital ManagementreportedNew York
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Samsara BioCapitalreportedPalo Alto
Sofinnova VenturesreportedMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$115.8M disclosed across 5 rounds · 2020–2025

▶$55.7MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen BradyExecutive Officer, Director
  • Reza DanaDirector
  • Kenneth HarrisonDirector
  • Marc de GaridelDirector
  • Meredith FisherDirector
  • Henry RathExecutive Officer
  • Susan OrrExecutive Officer
  • Michael DybbsDirector
  • Matt HobsonDirector
  • Maha RadhakrishnanDirector
  • Clarke AtwellExecutive Officer
  • Brian BaumExecutive Officer
Offering amount
$121.5M
Amount sold
$55.7M
Proceeds to insiders
$3.1M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedSep 2025 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Meredith FisherDirector
  • Reza DanaDirector
  • Kenneth HarrisonDirector
  • Henry RathExecutive Officer
  • Susan OrrExecutive Officer
  • Clarke AtwellExecutive Officer, Director
  • Marc de GaridelDirector
Offering amount
$2.3M
Amount sold
$2.3M
Proceeds to insiders
$610K
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.3MraisedMar 2025 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kenneth HarrisonDirector
  • Henry RathExecutive Officer
  • Marc de GaridelDirector
  • Meredith FisherDirector
  • Susan OrrExecutive Officer
  • Clarke AtwellExecutive Officer, Director
  • Reza DanaDirector
Offering amount
$3.3M
Amount sold
$3.3M
Proceeds to insiders
$610K
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedJan 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Henry RathExecutive Officer
  • Kenneth HarrisonDirector
  • Marc de GaridelDirector
  • Meredith FisherDirector
  • Reza DanaDirector
  • Clarke AtwellExecutive Officer, Director
  • Susan OrrExecutive Officer
Offering amount
$10M
Amount sold
$10M
Proceeds to insiders
$1.8M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$44.5MraisedOct 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Meredith FisherDirector
  • Marc de GaridelDirector
  • Kenneth HarrisonDirector
  • Clarke AtwellExecutive Officer, Director
  • Reza DanaDirector
Offering amount
$44.5M
Amount sold
$44.5M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Claris Biotherapeutics Raises $118M in Series B Fundingfinsmes.com · Aug 2026Claris Bio raises $118m for eye disease therapybioxconomy.com · Jul 2026Claris Bio Raises $118M to Take Eye Drop for Blindness into Phase III | Inside Precision Medicineinsideprecisionmedicine.com · Jul 2026Claris Bio raises USD 118m to advance first-ever pharmacologallsci.com · Jul 2026Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments | The Manila Timesmanilatimes.net · Jul 2026An eye drug biotech banks $118M and stocks its executive suite | BioPharma Divebiopharmadive.com · Jul 2026

Frequently asked questions

Who are Claris Biotherapeutics's investors?
Claris Biotherapeutics's investors include Catalio Capital Management, Novo Holdings, Samsara BioCapital, Sofinnova Ventures.
How much funding has Claris Biotherapeutics raised?
Claris Biotherapeutics has disclosed $115.8M raised across 5 rounds.
Where is Claris Biotherapeutics headquartered?
Claris Biotherapeutics is headquartered in Jersey City, US.
Claris Biotherapeutics — Investors & Founders | Fundraising Fox